Northwest Quadrant Wealth Management LLC Trims Stock Position in Johnson & Johnson $JNJ

Northwest Quadrant Wealth Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 6.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,468 shares of the company’s stock after selling 296 shares during the period. Johnson & Johnson comprises approximately 0.2% of Northwest Quadrant Wealth Management LLC’s portfolio, making the stock its 26th largest position. Northwest Quadrant Wealth Management LLC’s holdings in Johnson & Johnson were worth $683,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Financial Synergies Wealth Advisors Inc. purchased a new stake in Johnson & Johnson in the second quarter valued at $1,016,000. MB Levis & Associates LLC increased its stake in Johnson & Johnson by 1.2% in the second quarter. MB Levis & Associates LLC now owns 11,676 shares of the company’s stock valued at $1,783,000 after purchasing an additional 135 shares during the period. First Bancorp Inc ME increased its stake in Johnson & Johnson by 4.7% in the second quarter. First Bancorp Inc ME now owns 8,734 shares of the company’s stock valued at $1,334,000 after purchasing an additional 395 shares during the period. Wealthstream Advisors Inc. increased its stake in Johnson & Johnson by 3.4% in the second quarter. Wealthstream Advisors Inc. now owns 2,101 shares of the company’s stock valued at $321,000 after purchasing an additional 70 shares during the period. Finally, SAM Advisors LLC increased its stake in Johnson & Johnson by 3.0% in the second quarter. SAM Advisors LLC now owns 12,172 shares of the company’s stock valued at $1,859,000 after purchasing an additional 359 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. UBS Group lifted their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. The Goldman Sachs Group lifted their price objective on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Finally, Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $200.06.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.3%

Shares of Johnson & Johnson stock opened at $193.78 on Tuesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company’s 50-day simple moving average is $180.89 and its 200-day simple moving average is $165.18. The firm has a market cap of $466.68 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.